Home>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>BAY 73-1449

BAY 73-1449

Catalog No.GC61581

BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG.

Products are for research use only. Not for human use. We do not sell to patients.

BAY 73-1449 Chemical Structure

Cas No.: 693790-96-4

Size Price Stock Qty
10mM (in 1mL DMSO)
$306.00
In stock
5 mg
$278.00
In stock
10 mg
$464.00
In stock
25 mg
$881.00
In stock
50 mg
$1,437.00
In stock
100 mg
$2,178.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure[1].

BAY 73-1449 (0.1-1 mg/kg; i.v.) does not significantly reduce mesenteric inflow, but significantly reduces splenic shunt vessel outflow in rats[1].BAY 73-1449 (1-5 mg/kg, s.c. once daily for 7 d) has no effects on the degree of porto-systemic shunting in rats[1].BAY 73-1449 (1 mg/kg, s.c. once daily for 7 d), has no effects on portal pressures in rats[1]. Animal Model: Male Wistar rats (250-350 g) are ligated portal vein[1]

[1]. Bexis S, et, al. Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6.

Reviews

Review for BAY 73-1449

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BAY 73-1449

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.